Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02087579 · ClinicalTrials.gov registry record · Phase 1
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 305
- Enrollment target
NCT02087579 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 305 participants.
The verdict
NCT02087579, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 305 participants
- Enrollment target
Study Summary
The purpose of this study is to gather information about the steady-state plasma concentrations of aripiprazole, olanzapine, quetiapine and their relevant metabolites, at various dose levels and at different time points after dosing. In addition, comparison of capillary drug concentrations vs. venous drug concentrations will be performed for aripiprazole, olanzapine, paliperidone, quetiapine, risperidone and their relevant metabolites.
Interventions
- DRUG Aripiprazole, oral formulation
- DRUG Olanzapine, oral formulation
- DRUG Paliperidone, oral formulation
- DRUG Paliperidone, LAI
- DRUG Quetiapine, oral formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 305 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02087579
The ClinicalTrials.gov registry entry for NCT02087579 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 305 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Aripiprazole, oral formulation is the first listed.
NCT02087579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02087579 about?
NCT02087579 is a clinical study titled "Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants". The purpose of this study is to gather information about the steady-state plasma concentrations of aripiprazole, olanzapine, quetiapine and their relevant metabolites, at various dose levels and at different time points after dosing. In addition, comparison of capillary drug concentrations vs. venou...
What is the current status of trial NCT02087579?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 305 participants. The study started on 2014-02. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02087579?
The interventions under investigation include: Aripiprazole, oral formulation (DRUG), Olanzapine, oral formulation (DRUG), Paliperidone, oral formulation (DRUG), Paliperidone, LAI (DRUG), Quetiapine, oral formulation (DRUG).
Who is sponsoring clinical trial NCT02087579?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.